At what transferrin saturation percent is intravenous (IV) iron therapy indicated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 8, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

Iron infusions are indicated when the iron saturation percent is less than 20%. This recommendation is based on the guideline provided by the American Journal of Kidney Diseases, which states that if TSAT is < 20%, supplemental iron should be administered 1. The guideline also emphasizes the importance of maintaining TSAT > 20% to ensure adequate iron stores.

Key Considerations

  • The decision to administer iron infusions should be individualized based on the patient's clinical condition, severity of anemia, and underlying cause of iron deficiency.
  • Ferritin levels should also be considered, as there is insufficient evidence to recommend IV iron if ferritin > 500 ng/mL 1.
  • Common iron infusion preparations include iron sucrose, ferric carboxymaltose, and iron dextran, with dosing regimens varying by product.

Assessment and Monitoring

  • Before initiating iron infusions, a complete blood count, iron studies including ferritin, transferrin saturation, and renal function should be assessed.
  • Iron infusions work by bypassing the gastrointestinal absorption limitations of oral iron, directly replenishing iron stores and allowing for more efficient hemoglobin synthesis and red blood cell production.

Important Notes

  • The safety of IV iron administration when ferritin > 500 ng/mL has not been established, and therefore caution should be exercised in these cases 1.
  • The guideline provides a clear indication for iron infusions when TSAT is < 20%, but emphasizes the need for individualized decision-making and careful monitoring of patients receiving iron infusions.

From the FDA Drug Label

Inclusion criteria prior to randomization included ... ferritin ≤100 ng/mL or ferritin ≤300 ng/mL when transferrin saturation (TSAT) ≤30%. Inclusion criteria included hemoglobin (Hb) ≤11. 5 g/dL, ferritin ≤ 100 ng/mL or ferritin ≤300 ng/mL when transferrin saturation (TSAT) ≤ 30%. Iron deficiency was defined as serum ferritin <100 ng/mL or 100 to 300 ng/mL with TSAT <20%.

Iron infusions are indicated for patients with iron deficiency anemia with a transferrin saturation (TSAT) of ≤30% or <20% in certain cases 2.

From the Research

Iron Saturation Percent for Iron Infusions

  • Iron infusions are indicated for patients with iron deficiency when oral preparations are ineffective or cannot be used 3, 4.
  • The main treatment target for intravenous iron is an improvement of the quality of life, for which hemoglobin is a surrogate marker 5.
  • Iron deficiency is diagnosed by low serum ferritin or by transferrin saturation (iron/total iron binding capacity × 100) less than 20% 4.
  • According to current guidelines, iron deficiency is defined by a serum ferritin level <100 ng/ml or a transferrin saturation (TSAT) <20% if the serum ferritin level is 100-299 μg/L 6.
  • A low baseline TSAT-but not serum ferritin level-appears to be a reliable indicator of the effect of intravenous iron to reduce major heart failure events 6.
  • Iron deficiency state in patients with heart failure should be defined by a TSAT <20% (as long as the serum ferritin level is <400 μg/L) 6.

Key Indications for Iron Infusions

  • Oral iron intolerance or poor absorption 3, 4
  • Chronic inflammatory conditions (CKD, HF, IBD, cancer) 3, 4
  • Ongoing blood loss 4
  • During the second and third trimesters of pregnancy 4
  • Severe iron deficiency anemia 7

Important Considerations

  • Individual selection of the appropriate iron therapy and evaluation of treatment response are mandatory to safely deliver improved outcome through intravenous iron therapies 5.
  • Adverse events occurring with intravenous iron can be anticipated according to when they typically occur, which provides a basis for educating and preparing staff and patients on how iron infusions can be administered safely and efficiently 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.